Download PDF
Int J Sports Med 2022; 43(02): 183-191
DOI: 10.1055/a-1518-7953
Clinical Sciences

Decreased Native T1 Values and Impaired Myocardial Contractility in Anabolic Steroid Users

Francis Ribeiro de Souza
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Marcelo Rodrigues dos Santos
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Carlos Eduardo Rochitte
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Rafael Parenquine dos Santos
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Camila Paixão Jordão
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Ivanhoe Stuart Leite
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Guilherme Wesley Peixoto da Fonseca
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Rafael Almeida Fonseca
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Tiago Franco de Oliveira
2   Departamento de Farmacociências da Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
,
Maurício Yonamine
3   Departamento de Análises Clínicas e Toxicológicas da Faculdade de Ciências Farmacêuticas da Universidade de São Paulo, São Paulo, Brazil
,
Rosa Maria Rodrigues Pereira
4   Laboratório de Metabolismo Ósseo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
Carlos Eduardo Negrão
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
5   Escola de Educação Física e Esporte da Universidade de São Paulo, São Paulo, Brazil
,
de Nazaré Nunes Maria Janieire Alves
1   Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
› Author Affiliations Funding Ministério da Ciência, Tecnologia e Inovação > Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de São Paulo 2012/10527 Fundação Zerbini x
› Further Information
Also available at
    Permissions and Reprints

Abstract

Anabolic androgenic steroid (AAS) abuse leads to myocardial toxicity. Human studies are conflicting about the myocardial fibrosis in AAS users. We evaluated cardiac tissue characterization, left ventricle (LV) function, and cardiac structure by cardiovascular magnetic resonance (CMR). Twenty strength-trained AAS users (AASU) aged 29±5 yr, 20 strength-trained AAS nonusers (AASNU), and 7 sedentary controls (SC) were enrolled. Native T1 mapping, late-gadolinium enhancement (LGE), extracellular volume (ECV), and myocardial strain were evaluated. AASU showed lower Native T1 values than AASNU (888±162 vs. 1020±179 ms p=0.047). Focal myocardial fibrosis was found in 2 AASU. AASU showed lower LV radial strain (30±8 vs. 38±6%, p<0.01), LV circumferential strain (–17±3 vs. −20±2%, p<0.01), and LV global longitudinal strain (–17±3 vs. –20±3%, p<0.01) than AASNU by CMR. By echocardiography, AASU demonstrated lower 4-chamber longitudinal strain than AASNU (–15±g3 vs. –18±2%, p=0.03). ECV was similar among AASU, AASNU, and SC (28±10 vs. 28±7 vs. 30±7%, p=0.93). AASU had higher LV mass index than AASNU and SC (85±14 vs. 64±8 vs. 58±5 g/m2, respectively, p<0.01). AAS abuse may be linked to decreased myocardial native T1 values, impaired myocardial contractility, and focal fibrosis. These alterations may be associated with maladaptive cardiac hypertrophy in young AAS users.

Key words

T1 mapping - cardiac contractility - anabolic androgenic steroids

Supplementary Material



Publication History

Received: 10 December 2020

Accepted: 14 May 2021

Article published online:
02 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Forbes GB. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism 1985; 34: 571-573
    CrossrefPubMedGoogle Scholar
  • 2 Santos D, Sayegh ALC, Armani R. et al. Resting spontaneous baroreflex sensitivity and cardiac autonomic control in anabolic anogenic steroid users. Clinics (Sao Paulo) 2018; 73: e226
    CrossrefPubMedGoogle Scholar
  • 3 Montisci M, El Mazloum R, Cecchetto G. et al. Anabolic anogenic steroids abuse and cardiac death in athletes: Morphological and toxicological findings in four fatal cases. Forensic Sci Int 2012; 217: e13-e18
    CrossrefPubMedGoogle Scholar
  • 4 Alves MJ, Dos Santos, Dias RG. et al. Abnormal neurovascular control in anabolic anogenic steroids users. Med Sci Sports Exerc 2010; 42: 865-871
    CrossrefPubMedGoogle Scholar
  • 5 Porello RA, Dos Santos, Souza FR. et al. Neurovascular response during exercise and mental stress in anabolic steroid users. Med Sci Sports Exerc 2018; 50: 596-602
    CrossrefPubMedGoogle Scholar
  • 6 Morikawa AT, Maranhao RC, Alves MJ. et al. Effects of anabolic anogenic steroids on chylomicron metabolism. Steroids 2012; 77: 1321-1326
    CrossrefPubMedGoogle Scholar
  • 7 Souza FR, Dos Santos, Porello RA. et al. Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic anogenic steroid users. Atherosclerosis 2019; 283: 100-105
    CrossrefPubMedGoogle Scholar
  • 8 de Souza FR, Sales ARK, Dos Santos. et al. Retrograde and oscillatory shear rate in young anabolic anogenic steroid users. Scand J Med Sci Sports 2019; 29: 422-429
    CrossrefPubMedGoogle Scholar
  • 9 Baggish AL, Weiner RB, Kanayama G. et al. Cardiovascular toxicity of illicit anabolic-anogenic steroid use. Circulation 2017; 135: 1991-2002
    CrossrefPubMedGoogle Scholar
  • 10 Angell P, Chester N, Green D. et al. Anabolic steroids and cardiovascular risk. Sports Med 2012; 42: 119-134
    CrossrefPubMedGoogle Scholar
  • 11 Hoffman JR, Ratamess NA. Medical issues associated with anabolic steroid use: are they exaggerated?. J Sports Sci Med 2006; 5: 182-193
    PubMedGoogle Scholar
  • 12 Haaf P, Garg P. Messroghli et al. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: A comprehensive review. J Cardiovasc Magn Reson 2016; 18: 89
    CrossrefPubMedGoogle Scholar
  • 13 Olivotto I, Maron MS, Autore C. et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52: 559-566
    CrossrefPubMedGoogle Scholar
  • 14 Lusetti M, Licata M, Silingardi E. et al. Pathological changes in anabolic anogenic steroid users. J Forensic Leg Med 2015; 33: 101-104
    CrossrefPubMedGoogle Scholar
  • 15 Angell PJ, Ismail TF, Jabbour A. et al. Ventricular structure, function, and focal fibrosis in anabolic steroid users: A C study. Eur J Appl Physiol 2014; 114: 921-928
    CrossrefPubMedGoogle Scholar
  • 16 Rasmussen JJ, Schou M, Madsen PL. et al. Cardiac systolic dysfunction in past illicit users of anabolic anogenic steroids. Am Heart J 2018; 203: 49-56
    CrossrefPubMedGoogle Scholar
  • 17 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
    CrossrefPubMedGoogle Scholar
  • 18 Harriss DJ, MacSween A, Atkinson G. Ethical standards in sport and exercise science research: 2020 update. Int J Sports Med 2019; 40: 813-817
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Rogers T, Dabir D, Mahmoud I. et al. Standardization of T1 measurements with MOLLI in differentiation between health and disease--the ConSept study. J Cardiovasc Magn Reson 2013; 15: 78
    CrossrefPubMedGoogle Scholar
  • 20 Bandirali M, Lanza E, Messina C. et al. Dose absorption in lumbar and femoral dual energy X-ray absorptiometry examinations using three different scan modalities: an anthropomorphic phantom study. J Clin Densitom 2013; 16: 279-282
    CrossrefPubMedGoogle Scholar
  • 21 van de Kerkhof DH, de Boer D, Thijssen JH. et al. Evaluation of testosterone/epitestosterone ratio influential factors as determined in doping analysis. J Anal Toxicol 2000; 24: 102-115
    CrossrefPubMedGoogle Scholar
  • 22 Mantovani CC, Silva JPE, Forster G. et al. Simultaneous accelerated solvent extraction and hyolysis of 11-nor-Delta(9)-tetrahyocannabinol-9-carboxylic acid glucuronide in meconium samples for gas chromatography-mass spectrometry analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1074-1075: 1-7
    CrossrefPubMedGoogle Scholar
  • 23 Tahir E, Starekova J, Muellerleile K. et al. Myocardial fibrosis in competitive triathletes detected by contrast-enhanced C correlates with exercise-induced hypertension and competition history. JACC Cardiovasc Imaging 2018; 11: 1260-1270
    CrossrefPubMedGoogle Scholar
  • 24 McDiarmid AK, Swoboda PP, Erhayiem B. et al. Athletic cardiac adaptation in males is a consequence of elevated myocyte mass. Circ Cardiovasc Imaging 2016; 9: e003579
    CrossrefPubMedGoogle Scholar
  • 25 Swoboda PP, McDiarmid AK, Erhayiem B. et al. Assessing Myocardial Extracellular Volume by T1 Mapping to Distinguish Hypertrophic Cardiomyopathy From Athlete's Heart. J Am Coll Cardiol 2016; 67: 2189-2190
    CrossrefPubMedGoogle Scholar
  • 26 Robinson AA, Chow K, Salerno M. Myocardial T1 and ECV measurement: Underlying concepts and technical considerations. JACC Cardiovasc Imaging 2019; 12: 2332-2344
    CrossrefPubMedGoogle Scholar
  • 27 Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?. Heart 2004; 90: 496-501
    CrossrefPubMedGoogle Scholar
  • 28 Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart 2004; 90: 473-475
    CrossrefPubMedGoogle Scholar
  • 29 Wilson M, O'Hanlon R, Prasad S. et al. Diverse patterns of myocardial fibrosis in lifelong, veteran endurance athletes. J Appl Physiol (1985) 2011; 110: 1622-1626
    CrossrefPubMedGoogle Scholar
  • 30 Breuckmann F, Mohlenkamp S, Nassenstein K. et al. Myocardial late gadolinium enhancement: prevalence, pattern, and prognostic relevance in marathon runners. Radiology 2009; 251: 50-57
    CrossrefPubMedGoogle Scholar
  • 31 van de Schoor FR, Aengevaeren VL, Hopman MT. et al. Myocardial fibrosis in athletes. Mayo Clin Proc 2016; 91: 1617-1631
    CrossrefPubMedGoogle Scholar
  • 32 La Gerche A, Burns AT, Mooney DJ. et al. Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J 2012; 33: 998-1006
    CrossrefPubMedGoogle Scholar
  • 33 Mohlenkamp S, Lehmann N, Breuckmann F. et al. Running: The risk of coronary events : Prevalence and prognostic relevance of coronary atherosclerosis in marathon runners. Eur Heart J 2008; 29: 1903-1910
    CrossrefPubMedGoogle Scholar
  • 34 Papamitsou T, Barlagiannis D, Papaliagkas V. et al. Testosterone-induced hypertrophy, fibrosis and apoptosis of cardiac cells--an ultrastructural and immunohistochemical study. Med Sci Monit 2011; 17: BR266-BR273
    CrossrefPubMedGoogle Scholar
  • 35 Rocha FL, Carmo EC, Roque FR. et al. Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats. Am J Physiol Heart Circ Physiol 2007; 293: H3575-H3583
    CrossrefPubMedGoogle Scholar
  • 36 Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865
    PubMedGoogle Scholar
  • 37 Montisci M, El Mazloum R, Cecchetto G. et al. Anabolic anogenic steroids abuse and cardiac death in athletes: Morphological and toxicological findings in four fatal cases. Forensic Sci Int 2012; 217: e13-e18
    CrossrefPubMedGoogle Scholar
  • 38 Luijkx T, Velthuis BK, Backx FJ. et al. Anabolic androgenic steroid use is associated with ventricular dysfunction on cardiac MRI in strength trained athletes. Int J Cardiol 2013; 167: 664-668
    CrossrefPubMedGoogle Scholar
  • 39 Angell PJ, Chester N, Green DJ. et al. Anabolic steroid use and longitudinal, radial, and circumferential cardiac motion. Med Sci Sports Exerc 2012; 44: 583-590
    CrossrefPubMedGoogle Scholar
  • 40 Baggish AL, Weiner RB, Kanayama G. et al. Long-term anabolic-anogenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail 2010; 3: 472-476
    CrossrefPubMedGoogle Scholar
  • 41 Biering-Sorensen T, Biering-Sorensen SR, Olsen FJ. et al. Global longitudinal strain by echocardiography predicts long-term risk of cardiovascular morbidity and mortality in a low-risk general population: The Copenhagen City Heart Study. Circ Cardiovasc Imaging 2017; 10: e005521 doi: 10.1161/CIRCIMAGING.116.005521
    CrossrefPubMedGoogle Scholar
  • 42 D'Anea A, Radmilovic J, Caselli S. et al. Left atrial myocardial dysfunction after chronic abuse of anabolic anogenic steroids: A speckle tracking echocardiography analysis. Int J Cardiovasc Imaging 2018; 34: 1549-1559
    CrossrefPubMedGoogle Scholar
  • 43 Tahir E, Scherz B, Starekova J. et al. Acute impact of an endurance race on cardiac function and biomarkers of myocardial injury in triathletes with and without myocardial fibrosis. Eur J Prev Cardiol 2020; 27: 94-104
    CrossrefPubMedGoogle Scholar
  • 44 Kane GC, Karon BL, Mahoney DW. et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011; 306: 856-863
    PubMedGoogle Scholar
  • 45 Kosmala W, Jellis CL, Marwick TH. Exercise limitation associated with asymptomatic left ventricular impairment: Analogy with stage B heart failure. J Am Coll Cardiol 2015; 65: 257-266
    CrossrefPubMedGoogle Scholar
  • 46 Augustine DX, Howard L. Left ventricular hypertrophy in athletes: Differentiating physiology from pathology. Curr Treat Options Cardiovasc Med 2018; 20: 96
    CrossrefPubMedGoogle Scholar
  • 47 Sagoe D, McVeigh J, Bjornebekk A. et al. Polypharmacy among anabolic-anogenic steroid users: a descriptive metasynthesis. Subst Abuse Treat Prev Policy 2015; 10: 12
    CrossrefPubMedGoogle Scholar
  • 48 Kuhara S, Ishikawa H, Kanazawa T. Polarity-corrected TI prep tool for delayed-enhancement imaging and T1 mapping. Proc Intl Soc Mag Reson Med 2014; abstract 2447
    PubMed
  • 49 Ishikawa H, Seino S, Takasumi H. et al. The measurement precision and accuracy of t1 mapping using polarity corrected (PC) ti prep tool. Nihon Hoshasen Gijutsu Gakkai Zasshi 2018; 74: 13-21
    CrossrefPubMedGoogle Scholar